Cover Image

Analysis of body mass index, weight loss and progression of idiopathic pulmonary fibrosis

Nintedanib is an approved therapy for idiopathic pulmonary fibrosis (IPF). Some patients treated with nintedanib experience weight loss. Exploratory data suggest that low body mass index or weight loss are associated with worse outcomes in patients with IPF. We investigated whether BMI at baseline o...

Full description

Saved in:
Bibliographic Details
Main Authors: Jouneau, Stéphane (Author) , Crestani, Bruno (Author) , Thibault, Ronan (Author) , Lederlin, Mathieu (Author) , Vernhet, Laurent (Author) , Valenzuela, Claudia (Author) , Wijsenbeek, Marlies (Author) , Kreuter, Michael (Author) , Stansen, Wibke (Author) , Quaresma, Manuel (Author) , Cottin, Vincent (Author)
Format: Article (Journal)
Language:English
Published: 25 November 2020
In: Respiratory research
Year: 2020, Volume: 21
ISSN:1465-993X
DOI:10.1186/s12931-020-01528-4
Online Access:Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1186/s12931-020-01528-4
Verlag, lizenzpflichtig, Volltext: https://respiratory-research.biomedcentral.com/articles/10.1186/s12931-020-01528-4
Get full text
Author Notes:Stéphane Jouneau, Bruno Crestani, Ronan Thibault, Mathieu Lederlin, Laurent Vernhet, Claudia Valenzuela, Marlies Wijsenbeek, Michael Kreuter, Wibke Stansen, Manuel Quaresma and Vincent Cottin
Description
Summary:Nintedanib is an approved therapy for idiopathic pulmonary fibrosis (IPF). Some patients treated with nintedanib experience weight loss. Exploratory data suggest that low body mass index or weight loss are associated with worse outcomes in patients with IPF. We investigated whether BMI at baseline or weight loss over 52 weeks was associated with FVC decline, or influenced the effect of nintedanib, in patients with IPF.
Item Description:Gesehen am 27.01.2021
Physical Description:Online Resource
ISSN:1465-993X
DOI:10.1186/s12931-020-01528-4

Similar Items